Cidara Therapeutics Inc (NASDAQ:CDTX) has been given a consensus recommendation of “Buy” by the seven analysts that are currently covering the firm, MarketBeat Ratings reports. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $13.25.
Several research analysts have commented on CDTX shares. Cantor Fitzgerald set a $15.00 price objective on shares of Cidara Therapeutics and gave the company a “buy” rating in a research report on Tuesday, September 4th. Citigroup started coverage on shares of Cidara Therapeutics in a research report on Wednesday, July 25th. They set a “buy” rating and a $8.00 price objective for the company. Needham & Company LLC set a $14.00 target price on shares of Cidara Therapeutics and gave the stock a “buy” rating in a research note on Thursday, August 9th. Zacks Investment Research cut shares of Cidara Therapeutics from a “buy” rating to a “hold” rating in a research note on Monday, August 13th. Finally, ValuEngine raised shares of Cidara Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, July 11th.
Shares of CDTX opened at $4.12 on Friday. Cidara Therapeutics has a one year low of $3.36 and a one year high of $8.55. The company has a market cap of $107.94 million, a price-to-earnings ratio of -1.30 and a beta of 1.97. The company has a debt-to-equity ratio of 0.12, a current ratio of 7.11 and a quick ratio of 7.11.
Cidara Therapeutics (NASDAQ:CDTX) last announced its quarterly earnings data on Wednesday, August 8th. The biotechnology company reported ($1.13) EPS for the quarter, missing the consensus estimate of ($0.66) by ($0.47). On average, sell-side analysts anticipate that Cidara Therapeutics will post -2.53 earnings per share for the current fiscal year.
Hedge funds and other institutional investors have recently bought and sold shares of the business. BlackRock Inc. grew its stake in shares of Cidara Therapeutics by 265.0% during the first quarter. BlackRock Inc. now owns 249,540 shares of the biotechnology company’s stock worth $998,000 after buying an additional 181,177 shares during the last quarter. Granahan Investment Management Inc. MA bought a new stake in shares of Cidara Therapeutics during the second quarter worth $2,371,000. Opaleye Management Inc. bought a new stake in shares of Cidara Therapeutics during the second quarter worth $6,240,000. Stonepine Capital Management LLC bought a new stake in shares of Cidara Therapeutics during the second quarter worth $2,213,000. Finally, Omega Fund Management LLC grew its stake in shares of Cidara Therapeutics by 239.1% during the second quarter. Omega Fund Management LLC now owns 1,508,794 shares of the biotechnology company’s stock worth $7,846,000 after buying an additional 1,063,829 shares during the last quarter. 67.09% of the stock is currently owned by hedge funds and other institutional investors.
About Cidara Therapeutics
Cidara Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of anti-infectives for the treatment of diseases. Its lead product candidate is rezafungin acetate, a molecule in the echinocandin class of antifungals for the treatment and prevention of serious invasive fungal infections, including candidemia and invasive candidiasis, fungal infections associated with high mortality rates.
Featured Story: Stock Split
Receive News & Ratings for Cidara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cidara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.